Q2-osavuosiraportti
Vain PDF
23 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
1 355
Myynti
Määrä
6 154
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 25 | - | - | ||
| 2 500 | - | - | ||
| 5 000 | - | - | ||
| 6 873 | - | - | ||
| 326 | - | - |
Ylin
2,97VWAP
Alin
2,84VaihtoMäärä
0,2 60 266
VWAP
Ylin
2,97Alin
2,84VaihtoMäärä
0,2 60 266
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 73 351 | 73 351 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 73 351 | 73 351 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 11.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 26.8. | |
| Merkintäoikeusanti | 3.7. | |
| 2025 Ylimääräinen yhtiökokous | 2.7. | |
| 2024 Yhtiökokous | 14.5. | |
| 2025 Q1-osavuosiraportti | 5.5. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
11.9.·Why this big drop?
11.9.·Maybe some have sold large items but this stock will hold out.
8.9.·Positive Results from TrkA-NAM ACD137 Study in Knee Osteoarthritis Presented at Pain Conference AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that its presentation at the international pain conference NeuPSIG 2025 is now available on the company's website. The presentation includes data from preclinical studies with ACD137, the company's drug candidate in knee osteoarthritis-related pain.- 4.9.·AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that the company's presentation at the international pain conference NeuPSIG 2025 is now available in its entirety on the company's website. The presentation includes data from the Phase II clinical study with the company's lead clinical drug candidate in pain, ACD440. “Our data from the Phase II study with ACD440 showed that the substance reduces temperature-induced pain by approximately 50%, a significant and clinically relevant reduction. These positive data are in line with the results from the Phase Ib study and we have also demonstrated proof-of-mechanism in patients,” says Dr. Märta Segerdahl, MD, PhD, project leader and CMO at AlzeCure Pharma. The presentation, entitled The TRPV1 antagonist ACD440 Gel as a tool in pain precision medicine, results of a post hoc analysis, was given by Dr. Segerdahl and contains an analysis of the results from the clinical phase II study with ACD440, the lead drug candidate in the Painless platform. Data from the further analysis of the clinical study results from the phase IIa study with ACD440 in patients with chronic peripheral neuropathic pain show that ACD440 has powerful analgesic effects in particular in heat-induced pain, a common and distressing phenomenon for this patient group. This is also well consistent with the target mechanism of ACD440. ACD440 is a first-in-class TRPV1 antagonist in clinical phase that is being developed as a novel topical local treatment for peripheral neuropathic pain. The drug candidate, which was incorporated through a strategic in-licensing, originated in Big Pharma and is based on a strong scientific foundation, which was awarded a Nobel Prize in 2021. The substance is being developed as a gel for topical use, which keeps systemic exposure very low while maintaining high local concentrations of the substance for maximum analgesic effect and for a long period of time. ACD440 recently received orphan drug designation from the US FDA for the rare disease erythromelalgia, and has also received positive feedback from the FDA for a potential registration study for erythromelalgia. “The positive results from the completed proof-of-mechanism study in patients with peripheral neuropathic pain and the recent orphan drug designation from the FDA demonstrate the great potential value of ACD440, making the project interesting for both investors and pharmaceutical companies with a view to out-licensing,” says Martin Jönsson, CEO of AlzeCure Pharma AB. The abstract and poster are now available on AlzeCure’s website (https://www.alzecurepharma.se/sv/presentationer-och-intervjuer).
- 26.8.·“The second quarter of 2025 was once again an active and positive period for AlzeCure Pharma. In June, we received positive feedback from the US FDA regarding a potential registration-based Phase IIb/III study with our pain medication Painless ACD440, for the rare disease erythromelalgia. In July, we then received Orphan Drug Designation from the US Food and Drug Administration (FDA) for ACD440 for erythromelalgia, which is another confirmation of the strength of the project. We also started the procurement of the Phase II study with NeuroRestore ACD856, for which we have received a grant of EUR 2.5 million from the European Innovation Council (EIC), with the possibility of additional financing through the EIC fund. In order to finance and prepare this study, we announced a rights issue of SEK 48.5 million, with an over-allotment option of SEK 10 million. The issue was supported by all major shareholders, including SEB foundation, as well as by the company's board and management team via subscription commitments. The issue was subscribed to 212% and raised a total of SEK 58.5 million. We are very satisfied and proud of this good result and thank all participants in the issue for their trust and for supporting the plans that formed the basis for the issue. With these positive results, we look forward to delivering according to plan.” Martin Jönsson, CEO
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
Vain PDF
23 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11.9.·Why this big drop?11.9.·Maybe some have sold large items but this stock will hold out.
- 8.9.·Positive Results from TrkA-NAM ACD137 Study in Knee Osteoarthritis Presented at Pain Conference AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that its presentation at the international pain conference NeuPSIG 2025 is now available on the company's website. The presentation includes data from preclinical studies with ACD137, the company's drug candidate in knee osteoarthritis-related pain.
- 4.9.·AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that the company's presentation at the international pain conference NeuPSIG 2025 is now available in its entirety on the company's website. The presentation includes data from the Phase II clinical study with the company's lead clinical drug candidate in pain, ACD440. “Our data from the Phase II study with ACD440 showed that the substance reduces temperature-induced pain by approximately 50%, a significant and clinically relevant reduction. These positive data are in line with the results from the Phase Ib study and we have also demonstrated proof-of-mechanism in patients,” says Dr. Märta Segerdahl, MD, PhD, project leader and CMO at AlzeCure Pharma. The presentation, entitled The TRPV1 antagonist ACD440 Gel as a tool in pain precision medicine, results of a post hoc analysis, was given by Dr. Segerdahl and contains an analysis of the results from the clinical phase II study with ACD440, the lead drug candidate in the Painless platform. Data from the further analysis of the clinical study results from the phase IIa study with ACD440 in patients with chronic peripheral neuropathic pain show that ACD440 has powerful analgesic effects in particular in heat-induced pain, a common and distressing phenomenon for this patient group. This is also well consistent with the target mechanism of ACD440. ACD440 is a first-in-class TRPV1 antagonist in clinical phase that is being developed as a novel topical local treatment for peripheral neuropathic pain. The drug candidate, which was incorporated through a strategic in-licensing, originated in Big Pharma and is based on a strong scientific foundation, which was awarded a Nobel Prize in 2021. The substance is being developed as a gel for topical use, which keeps systemic exposure very low while maintaining high local concentrations of the substance for maximum analgesic effect and for a long period of time. ACD440 recently received orphan drug designation from the US FDA for the rare disease erythromelalgia, and has also received positive feedback from the FDA for a potential registration study for erythromelalgia. “The positive results from the completed proof-of-mechanism study in patients with peripheral neuropathic pain and the recent orphan drug designation from the FDA demonstrate the great potential value of ACD440, making the project interesting for both investors and pharmaceutical companies with a view to out-licensing,” says Martin Jönsson, CEO of AlzeCure Pharma AB. The abstract and poster are now available on AlzeCure’s website (https://www.alzecurepharma.se/sv/presentationer-och-intervjuer).
- 26.8.·“The second quarter of 2025 was once again an active and positive period for AlzeCure Pharma. In June, we received positive feedback from the US FDA regarding a potential registration-based Phase IIb/III study with our pain medication Painless ACD440, for the rare disease erythromelalgia. In July, we then received Orphan Drug Designation from the US Food and Drug Administration (FDA) for ACD440 for erythromelalgia, which is another confirmation of the strength of the project. We also started the procurement of the Phase II study with NeuroRestore ACD856, for which we have received a grant of EUR 2.5 million from the European Innovation Council (EIC), with the possibility of additional financing through the EIC fund. In order to finance and prepare this study, we announced a rights issue of SEK 48.5 million, with an over-allotment option of SEK 10 million. The issue was supported by all major shareholders, including SEB foundation, as well as by the company's board and management team via subscription commitments. The issue was subscribed to 212% and raised a total of SEK 58.5 million. We are very satisfied and proud of this good result and thank all participants in the issue for their trust and for supporting the plans that formed the basis for the issue. With these positive results, we look forward to delivering according to plan.” Martin Jönsson, CEO
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
1 355
Myynti
Määrä
6 154
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 25 | - | - | ||
| 2 500 | - | - | ||
| 5 000 | - | - | ||
| 6 873 | - | - | ||
| 326 | - | - |
Ylin
2,97VWAP
Alin
2,84VaihtoMäärä
0,2 60 266
VWAP
Ylin
2,97Alin
2,84VaihtoMäärä
0,2 60 266
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 73 351 | 73 351 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 73 351 | 73 351 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 11.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 26.8. | |
| Merkintäoikeusanti | 3.7. | |
| 2025 Ylimääräinen yhtiökokous | 2.7. | |
| 2024 Yhtiökokous | 14.5. | |
| 2025 Q1-osavuosiraportti | 5.5. |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
Vain PDF
23 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 11.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 26.8. | |
| Merkintäoikeusanti | 3.7. | |
| 2025 Ylimääräinen yhtiökokous | 2.7. | |
| 2024 Yhtiökokous | 14.5. | |
| 2025 Q1-osavuosiraportti | 5.5. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 11.9.·Why this big drop?11.9.·Maybe some have sold large items but this stock will hold out.
- 8.9.·Positive Results from TrkA-NAM ACD137 Study in Knee Osteoarthritis Presented at Pain Conference AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that its presentation at the international pain conference NeuPSIG 2025 is now available on the company's website. The presentation includes data from preclinical studies with ACD137, the company's drug candidate in knee osteoarthritis-related pain.
- 4.9.·AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced today that the company's presentation at the international pain conference NeuPSIG 2025 is now available in its entirety on the company's website. The presentation includes data from the Phase II clinical study with the company's lead clinical drug candidate in pain, ACD440. “Our data from the Phase II study with ACD440 showed that the substance reduces temperature-induced pain by approximately 50%, a significant and clinically relevant reduction. These positive data are in line with the results from the Phase Ib study and we have also demonstrated proof-of-mechanism in patients,” says Dr. Märta Segerdahl, MD, PhD, project leader and CMO at AlzeCure Pharma. The presentation, entitled The TRPV1 antagonist ACD440 Gel as a tool in pain precision medicine, results of a post hoc analysis, was given by Dr. Segerdahl and contains an analysis of the results from the clinical phase II study with ACD440, the lead drug candidate in the Painless platform. Data from the further analysis of the clinical study results from the phase IIa study with ACD440 in patients with chronic peripheral neuropathic pain show that ACD440 has powerful analgesic effects in particular in heat-induced pain, a common and distressing phenomenon for this patient group. This is also well consistent with the target mechanism of ACD440. ACD440 is a first-in-class TRPV1 antagonist in clinical phase that is being developed as a novel topical local treatment for peripheral neuropathic pain. The drug candidate, which was incorporated through a strategic in-licensing, originated in Big Pharma and is based on a strong scientific foundation, which was awarded a Nobel Prize in 2021. The substance is being developed as a gel for topical use, which keeps systemic exposure very low while maintaining high local concentrations of the substance for maximum analgesic effect and for a long period of time. ACD440 recently received orphan drug designation from the US FDA for the rare disease erythromelalgia, and has also received positive feedback from the FDA for a potential registration study for erythromelalgia. “The positive results from the completed proof-of-mechanism study in patients with peripheral neuropathic pain and the recent orphan drug designation from the FDA demonstrate the great potential value of ACD440, making the project interesting for both investors and pharmaceutical companies with a view to out-licensing,” says Martin Jönsson, CEO of AlzeCure Pharma AB. The abstract and poster are now available on AlzeCure’s website (https://www.alzecurepharma.se/sv/presentationer-och-intervjuer).
- 26.8.·“The second quarter of 2025 was once again an active and positive period for AlzeCure Pharma. In June, we received positive feedback from the US FDA regarding a potential registration-based Phase IIb/III study with our pain medication Painless ACD440, for the rare disease erythromelalgia. In July, we then received Orphan Drug Designation from the US Food and Drug Administration (FDA) for ACD440 for erythromelalgia, which is another confirmation of the strength of the project. We also started the procurement of the Phase II study with NeuroRestore ACD856, for which we have received a grant of EUR 2.5 million from the European Innovation Council (EIC), with the possibility of additional financing through the EIC fund. In order to finance and prepare this study, we announced a rights issue of SEK 48.5 million, with an over-allotment option of SEK 10 million. The issue was supported by all major shareholders, including SEB foundation, as well as by the company's board and management team via subscription commitments. The issue was subscribed to 212% and raised a total of SEK 58.5 million. We are very satisfied and proud of this good result and thank all participants in the issue for their trust and for supporting the plans that formed the basis for the issue. With these positive results, we look forward to delivering according to plan.” Martin Jönsson, CEO
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
1 355
Myynti
Määrä
6 154
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 25 | - | - | ||
| 2 500 | - | - | ||
| 5 000 | - | - | ||
| 6 873 | - | - | ||
| 326 | - | - |
Ylin
2,97VWAP
Alin
2,84VaihtoMäärä
0,2 60 266
VWAP
Ylin
2,97Alin
2,84VaihtoMäärä
0,2 60 266
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 73 351 | 73 351 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 73 351 | 73 351 | 0 | 0 |